Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 138

1.

T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients.

Viborg N, Ramskov S, Andersen RS, Sturm T, Fugmann T, Bentzen AK, Rafa VM, Straten PT, Svane IM, Met Ö, Hadrup SR.

Oncoimmunology. 2019 Sep 30;8(12):e1663107. doi: 10.1080/2162402X.2019.1663107. eCollection 2019.

2.

TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting.

Peeters MJW, Rahbech A, Thor Straten P.

Cancer Immunol Immunother. 2020 Feb;69(2):237-244. doi: 10.1007/s00262-019-02421-w. Epub 2019 Oct 29. Review.

3.

Inflammation induced PD-L1-specific T cells.

Munir S, Lundsager MT, Jørgensen MA, Hansen M, Petersen TH, Bonefeld CM, Friese C, Met Ö, Straten PT, Andersen MH.

Cell Stress. 2019 Sep 13;3(10):319-327. doi: 10.15698/cst2019.10.201.

4.

Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome.

Hu T, Buus TB, Krejsgaard T, Nansen A, Lundholt BK, Spee P, Fredholm S, Petersen DL, Blümel E, Gluud M, Monteiro MN, Willerslev-Olsen A, Andersen MH, Straten PT, Met Ö, Stolearenco V, Fogh H, Gniadecki R, Nastasi C, Litman T, Woetmann A, Gjerdrum LMR, Ødum N.

Oncotarget. 2019 Aug 6;10(47):4894-4906. doi: 10.18632/oncotarget.27122. eCollection 2019 Aug 6.

5.

MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells.

Peeters MJW, Dulkeviciute D, Draghi A, Ritter C, Rahbech A, Skadborg SK, Seremet T, Carnaz Simões AM, Martinenaite E, Halldórsdóttir HR, Andersen MH, Olofsson GH, Svane IM, Rasmussen LJ, Met Ö, Becker JC, Donia M, Desler C, Thor Straten P.

Cancer Immunol Res. 2019 Sep;7(9):1472-1484. doi: 10.1158/2326-6066.CIR-18-0841. Epub 2019 Jul 2.

PMID:
31266785
6.

Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1270. doi: 10.1074/mcp.W119.001571. No abstract available.

7.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1255-1268. doi: 10.1074/mcp.RA119.001524.

PMID:
31154438
8.

Collagen density regulates the activity of tumor-infiltrating T cells.

Kuczek DE, Larsen AMH, Thorseth ML, Carretta M, Kalvisa A, Siersbæk MS, Simões AMC, Roslind A, Engelholm LH, Noessner E, Donia M, Svane IM, Straten PT, Grøntved L, Madsen DH.

J Immunother Cancer. 2019 Mar 12;7(1):68. doi: 10.1186/s40425-019-0556-6.

9.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
10.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
11.

Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model.

Idorn M, Skadborg SK, Kellermann L, Halldórsdóttir HR, Holmen Olofsson G, Met Ö, Thor Straten P.

Oncoimmunology. 2018 Apr 18;7(8):e1450715. doi: 10.1080/2162402X.2018.1450715. eCollection 2018.

12.

Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site.

Idorn M, Thor Straten P.

Cells. 2018 Aug 17;7(8). pii: E108. doi: 10.3390/cells7080108. Review.

13.

Genetically engineered cell factories produce glycoengineered vaccines that target antigen-presenting cells and reduce antigen-specific T-cell reactivity.

Mathiesen CBK, Carlsson MC, Brand S, Möller SR, Idorn M, Thor Straten P, Pedersen AE, Dabelsteen S, Halim A, Würtzen PA, Brimnes J, Ipsen H, Petersen BL, Wandall HH.

J Allergy Clin Immunol. 2018 Dec;142(6):1983-1987. doi: 10.1016/j.jaci.2018.07.030. Epub 2018 Aug 17. No abstract available.

PMID:
30125661
14.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2018 Nov;17(11):2132-2145. doi: 10.1074/mcp.RA118.000792. Epub 2018 Aug 2. Retraction in: Mol Cell Proteomics. 2019 Jun;18(6):1270.

15.

Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction.

Idorn M, Olsen M, Halldórsdóttir HR, Skadborg SK, Pedersen M, Høgdall C, Høgdall E, Met Ö, Thor Straten P.

Oncoimmunology. 2017 Dec 26;7(4):e1412029. doi: 10.1080/2162402X.2017.1412029. eCollection 2018.

16.

Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.

Rius C, Attaf M, Tungatt K, Bianchi V, Legut M, Bovay A, Donia M, Thor Straten P, Peakman M, Svane IM, Ott S, Connor T, Szomolay B, Dolton G, Sewell AK.

J Immunol. 2018 Apr 1;200(7):2263-2279. doi: 10.4049/jimmunol.1700242. Epub 2018 Feb 26.

17.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

18.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM.

Cancer Res. 2017 Sep 1;77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. Epub 2017 Jun 27.

19.

Exercise and cancer: from "healthy" to "therapeutic"?

Idorn M, Thor Straten P.

Cancer Immunol Immunother. 2017 May;66(5):667-671. doi: 10.1007/s00262-017-1985-z. Epub 2017 Mar 21. Review.

20.

Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial.

Jørgensen NG, Ahmad SM, Abildgaard N, Straten PT, Svane IM, Andersen MH, Knudsen LM.

Stem Cell Investig. 2016 Dec 23;3:95. doi: 10.21037/sci.2016.11.09. eCollection 2016.

Supplemental Content

Loading ...
Support Center